Alnylam Pharmaceuticals admitted defeat, for now, in a lawsuit in Delaware federal court that accused Moderna's blockbuster ...

Newly launched Judo Bio aims to develop ligand-siRNA conjugates through its Selectively Targeting RNA Into KidnEy (STRIKE) ...

With the business potentially at an important milestone, we thought we'd take a closer look at Alnylam Pharmaceuticals, ...

Alnylam Pharmaceuticals has conceded that Moderna's products do not infringe on its patents, as a court ruling determined.

Taking the mat is Judo Bio, an up-and-coming biotech armed with $100 million to develop oligonucleotide medicines targeting ...

Fidelity Investments, an investment management company, released its “Fidelity Growth Strategies Fund” second quarter 2024 ...

RNA biotech CAMP4 Therapeutics has marked out plans for a $67 million IPO, with inflammation-focused Upstream Bio pegging its ...

The venture capital firm Atlas Venture is launching a start-up that aims to develop antisense oligonucleotides for a ...

Michael Ulz, an analyst from Morgan Stanley, maintained the Hold rating on Alnylam Pharma (ALNY – Research Report). The associated price ...

In a report released yesterday, Whitney Ijem from Canaccord Genuity maintained a Buy rating on Alnylam Pharma (ALNY – Research Report), ...

US RNAi therapeutics company Alnylam Pharmaceuticals has released two new data sets from the HELIOS-B Phase III study of ...